Moderna's mRNA-1010 flu vaccine demonstrated 27 percent higher efficacy than standard flu vaccinations, based on a trial involving nearly 41,000 older adults. The efficacy was reported at 26.6 percent for all participants and 27.4 percent for those aged 65 and older. This trial followed one of the most severe flu seasons in years, with an estimated 770,000 hospitalizations reported. Executive statements emphasized the importance of the results, highlighting the potential for mRNA vaccines to match circulating strains and support rapid responses to outbreaks.
Moderna's new mRNA-based flu vaccine, mRNA-1010, demonstrated a 27 percent higher efficacy rate in preventing influenza infections compared to the standard flu shot in a trial with nearly 41,000 participants aged 50 and older.
The trial showed that mRNA-1010 had an overall vaccine efficacy that was 26.6 percent higher than the standard shot and 27.4 percent higher in those aged 65 and older.
Positive trial results highlight the need for more effective vaccines, especially after one of the worst flu seasons, with estimates of 770,000 hospitalizations in the US.
'Today's strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults,' said Moderna CEO Stéphane Bancel.
Collection
[
|
...
]